SLC5A2 and Fabry disease: The most recent Expert Consensus on practical clinical recommendations and guidance for patients with classic Fabry disease includes a statement of the potential expected benefit of the combined treatment with recombinant enzyme or oral chaperone with adjunctive kidney protective therapies such as RAS blockade and SGLT2 inhibitor, but the experts conclude that they were unable to identify any evidence from clinical trials to support this recommendation [165].